Sign In
Buy MYOV
$26.98
+0 (+0%)
At Close: Jun 08, 2023
Myovant Sciences Appoints Industry Veteran David Marek as Chief Executive Officer
06:58am, Monday, 04'th Jan 2021
BASEL, Switzerland, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of David
Myovant (MYOV) Up on Collaboration With Pfizer for Relugolix
11:17am, Tuesday, 29'th Dec 2020
Myovant Sciences (MYOV) and Pfizer enter collaboration agreement to develop and commercialize relugolix monotherapy and combination regimen for prostate cancer and uterine fibroids, respectively.
MYOV Stock Price Increased 20.48%: Why It Happened
07:42am, Tuesday, 29'th Dec 2020
The stock price of Myovant Sciences Ltd. (MYOV) increased by 20.48% as it went from a previous close of $22.75 to $27.41 between December 27 and December 28.
Why These 4 Health Care Stocks Are Moving Today
02:10pm, Monday, 28'th Dec 2020
Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multiple scler
Myovant leaps 35% on Pfizer partnership for development of prostate-cancer drug
12:07pm, Monday, 28'th Dec 2020
Shares of Myovant surged as much as 35% to $30 on Monday after the biopharmaceutical company announced a partnership with Pfizer to develop and commercialize a drug for the treatment of prostate cance
Myovant shares soar 27% on news of Pfizer prostate cancer drug collaboration worth up to $4.2 billion
12:01pm, Monday, 28'th Dec 2020
Shares of Myovant Sciences soared 27% Monday, after its parent Sumitovant Biopharma unveiled an agreement with Pfizer Inc. to jointly develop a treatment for prostate cancer and women's health in a de
Why Myovant Sciences Stock Is Soaring Today
11:30am, Monday, 28'th Dec 2020
Investors are cheering a big collaboration with Pfizer.
Why This Recently Approved Prostate Cancer Treatment Could Be Huge for Myovant
10:59am, Monday, 28'th Dec 2020
Myovant Sciences Ltd. (NYSE: MYOV) shares shot up on Monday after the company announced a new collaboration with the pharmaceutical giant Pfizer Inc.
Deal With Pfizer Sends Myovant Shares Higher: What Investors Need To Know
10:50am, Monday, 28'th Dec 2020
Myovant Sciences Ltd (NYSE: MYOV) stock is adding about one-fourth of its market capitalization Monday following a licensing deal with Pfizer Inc. (NYSE: PFE). What Happened: Myovant announced a coll
Biopharmaceutical Stock Surges Thanks to Pfizer Partnership
10:40am, Monday, 28'th Dec 2020
The shares of Myovant Sciences Ltd (NYSE:MYOV) are up 27.2% at $29.08 at last check, gapping to record highs, after the biopharmaceutical concern announced a collaboration with Pfizer (PFE) to develo
Myovant shares soar 16% premarket on news of Pfizer cancer drug deal worth up to $4.2 billion
07:28am, Monday, 28'th Dec 2020
Shares of Myovant Sciences soared 16% in premarket trade Monday, after its parent Sumitovant Biopharma said Myovant will work with Pfizer Inc. to jointly develop a treatment for men's and women's canc
Myovant and Pfizer to jointly develop and commercialize ORGOVYXTM (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and CanadaMyovant to receive an upfront paymen
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health
06:30am, Monday, 28'th Dec 2020
BASEL, Switzerland and NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced a collaboration to develop and commercialize relugolix –
Myovant Sciences: Is The Ultimate Catalyst Coming?
08:49am, Tuesday, 22'nd Dec 2020
Riding strong data, Myovant recently secured FDA approval for relugolix in treating advanced prostate cancer. Under the brand Orgovyx, Myovant will market the said drug as soon as in January.
•ORGOVYX is the first approved therapy in the Sumitovant Biopharma family of companies •ORGOVYX is the first approved therapy in the Sumitovant Biopharma family of companies
